The Hygiology Post ® is presenting information about a company that seems to have much potential to help many people. Both 2012 and 2013 appear to be pivotal years in determining how helpful the patented technologies may actually be for people. Senesco Technologies has continued to update information on its web site (https://www.senesco.com/; retrieved on 11-13-2013). As a matter of disclosure : The author continues to be a current shareholder in the company.
A recent article in the publication, Seeking Alpha https://seekingalpha.com/article/1822422-as-dosage-escalates-so-could-the-market-valuation-of-senesco?source=yahoo; retrieved on 11-13-2013), titled “As Dosage Escalates, So Could The Market Valuation Of Senesco” on “Nov 8 2013, 10:32 by: George Ronan” began the following way:
“Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.
An experienced biotechnology investor will know that when it comes to pre-approed healthcare stocks, news and investor sentiment control price. Generally, in the case of a successful healthcare company, consistently positive trial data will gradually inflate a stock’s price until the point at which a drug receives FDA approval. On the announcing of FDA approval, the share price of the company in question will increase dramatically, fueled by investor expectation of either lucrative market access or big pharma acquisition, or both. There may be volatility along the way, as sentiment ebbs and flows, but overall this is the path a successful healthcare stock will take. Common sense suggests the earlier an investor takes a position, the higher the reward. For some reason however, the stock of one healthcare company is not following this pattern. Despite consistently positive data, the market currently prices Senesco (OTC:SNTID) shares at a 61% discount to where they started the year. If investor sentiment is the only factor driving this unorthodox behavior, Senesco stock could currently be one of the most undervalued assets available.”
The Hygiology Post ® welcomes feedback from readers as to whether the articles (individually and/or collectively) help fulfill its vision and mission.
Louis DeCola, Jr. © 2013 The Hygiology Post ®